Genomic Health (GHDX) Q4 Revenue Tops Views, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Join SI Premium – FREE
Genomic Health (NASDAQ: GHDX) reported Q4 EPS of $0.23, may not compare to the analyst estimate of $0.30. Revenue for the quarter came in at $104.6 million versus the consensus estimate of $101.51 million.
GUIDANCE:
Genomic Health sees FY2019 EPS of $1.38-$1.54, versus the consensus of $1.25. Genomic Health sees FY2019 revenue of $436-448 million, versus the consensus of $438.82 million.
For earnings history and earnings-related data on Genomic Health (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- nVent Electric (NVT) Tops Q3 EPS by 13c ; Offers Guidance
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
